-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Tcr2 Therapeutics Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q4 2019 to Q1 2023.
- Tcr2 Therapeutics Inc. Income Tax Expense (Benefit) for the quarter ending March 31, 2023 was $3K, a 91.7% decline year-over-year.
- Tcr2 Therapeutics Inc. Income Tax Expense (Benefit) for the twelve months ending March 31, 2023 was $228K, a 21.1% decline year-over-year.
- Tcr2 Therapeutics Inc. annual Income Tax Expense (Benefit) for 2022 was $261K, a 9.69% decline from 2021.
- Tcr2 Therapeutics Inc. annual Income Tax Expense (Benefit) for 2021 was $289K, a 79.5% increase from 2020.
- Tcr2 Therapeutics Inc. annual Income Tax Expense (Benefit) for 2020 was $161K, a 57.8% increase from 2019.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)